USA flag logo/image

An Official Website of the United States Government

Specific Tool for Modeling Neuronal Degeneration

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
29645
Program Year/Program:
1995 / SBIR
Agency Tracking Number:
29645
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ADVANCED TARGETING SYSTEMS, INC.
10451 Roselle St #300 SAN DIEGO, CA 92121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1995
Title: Specific Tool for Modeling Neuronal Degeneration
Agency: HHS
Contract: 1 R43 NS34591-01,
Award Amount: $96,844.00
 

Abstract:

Alzheimer's disease (AD) is a common, devastating neurodegenerative disorder characterized by progrcognitive decline. Loss of the cholinergic innervation of limbic structures and the neocortex occursin patients with AD. The degree of cognitive decline has been correlated to the extent of cholinergineocortex and loss of cholinergic neurons from the basal forebrain (CBF). The development of pharmacthe treatment of this disease has been hindered by the lack of a suitable animal model. Animal modeldegeneration of AD have been attempted through the use of lesioning agents--electrolytic or neurotoxnot been sufficiently specific, do not produce an efficient cell kill, or both and this has left thethe disease. The neurons of the CBF express p75, the low affinity neurotrophin receptor, and are theexpress this antigen. Recently, we have created a new cytotoxin, 192-IgU-SAP, that has been reportedspecific for rat CBF neurons that are p75 positive and produces almost complete kill of cholinergichas been reported to be a superior agent for the creation of AD-like neuronal degeneration in the rathe reagent is its lack of activity in the mouse. The mouse is the species of choice for many neuroswell-characterized molecular biology and chemistry of its brain, the recent widespread use of transgtechniques and the low cost and rapid breeding of the animal. In Phase I we will create a new reagenthe mouse to cause specific lesioning of CBF neurons and allow the development of a mouse model fordegeneration of AD.

Principal Investigator:

Douglas Lappi
61938

Business Contact:

Small Business Information at Submission:

Advanced Targeting Systems,
Box 910547 San Diego, CA 92191

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No